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Infertility affects about one in seven couples, many of whom seek medical help to have a child. 1 Although numerous new fertility interventions and products have been developed over the past decade, there are concerns that some might not be evidence based and that some clinics may be offering additional services that are not based on the most up-to-date research. 2 In vitro fertilisation (IVF) is expensive-a single cycle can cost £5000 (€5800; $6200)-and places considerable financial burden on patients, especially as 59% of procedures are not NHS funded. 3 On top of this UK fertility treatment centres offer a range of additional investigations and treatments, 4 costing from £50 for a single screening blood test to as much as £8000 for egg freezing packages (box 1).
Guidance from the UK regulator, the Human Fertilisation and Embryology Authority (HFEA), suggests questions that couples might want to ask before deciding on treatment. 2 These include: Is this treatment recommended by the National Institute for Health and Care Excellence (NICE) and, if not, why not? Has this treatment been subjected to randomised controlled clinical trials that show it is effective and is there a Cochrane review available? Are there any adverse effects or risks (known or potential) of the treatment? 2 Given concerns over the evidence base for fertility treatments and the implications for patients we set out to answer these questions.
What did we do?
We obtained from HFEA a list of all UK centres providing fertility treatments and examined their websites. From these sites we compiled a list of interventions offered in addition to standard IVF that are claimed to improve fertility outcomes. 4 We excluded interventions aimed at patients with a pre-existing disease such as diabetes, diagnosed conditions such as polycystic ovarian syndrome, or neurological conditions such as spinal cord injury; we excluded interventions related to donation of sperm or eggs; and we excluded complementary therapies such as homeopathy and nutrition. This gave a list of 38 fertility interventions. We classified 27 of these as add-on interventions, six as alternatives to IVF, and five as treatments for preservation of fertility (box 2).
For these 38 additional fertility interventions, we searched for evidence as HFEA suggests, focusing on the key outcome of live birth rates (see table A on thebmj.com). Nine researchers (NB, DC, OG, KM, DN, IO, AP, ES, JOS) independently searched Medline and the Cochrane library for systematic reviews and randomised controlled trials in April 2016. When we could not find any randomised controlled trials, we looked for the next highest level of available evidence (eg, observational study) and categorised the evidence found using the Oxford Centre for Evidence Based Medicine levels of evidence. 5 We also searched the Cochrane reviews and NICE guidance CG156 for information on harms up to September 2016. Egg freezing packages-up to £8000
What did we find?

Box 2: Fertility interventions offered by UK centres
Add-ons (n=27)
Ovarian reserve test/ anti-mullerian hormone and antral follicle count including 59 systematic reviews of the effectiveness of assisted reproductive technologies. 6 These reviews reported that five of the 38 interventions improved live birth outcomes; for 13 interventions, the evidence was insufficient to make a summary estimate, and for seven there was evidence that the intervention did not improve live birth rates. For preimplantation genetic screening older methods worsened outcomes, but there was some evidence of benefit for more recently developed techniques.
The five interventions for which we found evidence of improvements in live birth rates were blastocyst culture, endometrial scratching, adherence compounds, oral antioxidants, and intrauterine insemination in a natural cycle. However, for all of these interventions, the supporting studies had methodological problems that raise uncertainty about the results (table⇓).
We also identified one review that showed a negative effect. A 2006 Cochrane review of nine trials of preimplantation genetic screening concluded that it significantly lowered live birth rate, 12 and a 2009 review also found no benefit. 13 Newer techniques such as array comparative genomic hybridisation have subsequently been introduced. We identified a 2015 systematic review not done by the Cochrane group assessing four randomised trials of the newer techniques, targeted generally at younger women. 14 In one trial delivery rates per cycle were higher in the intervention group than the control group but in the pooled analysis including cohort studies, there was no significant effect. NHS England's 2013 clinical commissioning policy reports that in the "absence of evidence of its clinical and cost effectiveness, there is no intention to support the introduction of preimplantation genetic screening into NHS clinical practice." 15 For 11 interventions we were unable to find systematic review evidence (figure⇓). For eight of these we identified only a single randomised trial or observational study, none of which showed benefit. For three interventions (segmented IVF, dummy embryo transfer, and quad therapy) we were unable to find any evidence beyond expert opinion or mechanism of action.
Known or potential adverse effects or risks
NICE guidance was not helpful about harms, providing comment for only two interventions (intracytoplasmic sperm injection (ICSI) and ovulation induction and cycle monitoring). For IVF with or without ICSI, NICE guidance states that women should be informed that the absolute risks of long term adverse outcomes are low but that a small increased risk of ovarian tumours cannot be excluded (table B on The Cochrane reviews gave limited information on harms. In many cases the included trials provided no information, inadequate information, or inconsistently reported information on adverse events. For example, the review on assisted hatching reported that miscarriage rates were similar in both groups and multiple pregnancy rates were significantly increased in the assisted hatching group. However, there were insufficient data on ectopic pregnancy, congenital or chromosomal abnormalities, blastocyst formation, or embryo damage. 16
How robust is the evidence?
Of the 38 interventions we reviewed, there are only 11 for which NICE guidance recommends use in targeted populations. Our appraisal of the evidence shows only one intervention, endometrial scratching, for which the review evidence robustly supports an increase in live birth rate, yet even this evidence is of only moderate quality, and the observed benefit is only in women with more than two previous embryo transfers. A UK multicentre trial is investigating the use of endometrial injury in women undergoing IVF for the first time, which should provide relevant information for a broader patient population. 17
Cochrane systematic reviews cover less than half of the available treatments. To find information we had to look at other reviews or lower quality evidence, some of which is not freely available to the public. The reporting of harms was poor and therefore for many treatments it is impossible to be informed about adverse effects.
There is an urgent need for randomised controlled trials for many interventions that are currently being offered. Treatments with uncertain effects (benefits and harms) should be licensed for use only in the context of meaningful research. The benefits and harms of simultaneous use of multiple interventions are also not known.
Providing better evidence
People seeking fertility treatment need good quality evidence to make informed choices. The current approach by HFEA leaves patients and clinicians to seek evidence for themselves or from staff in private clinics selling fertility services. We do not believe this approach is realistic. Patients may be desperate, and therefore vulnerable, and we have shown that fertility interventions are offered without supporting evidence to back up claims of effect. 4
Patients are unlikely to have specialist skills in seeking and critically appraising clinical evidence. For complex issues such as genetic screening we consider the HFEA's advice, that "you should talk to your GP to go through the options available," unreasonable, as there is likely to be insufficient knowledge available to correctly reflect the potential benefits and harms of such interventions. 2 Furthermore, there are no maintained relevant information resources appropriate for use by non-clinicians. Initiatives such as PubMed Health and Cochrane's plain language summaries are welcome but they need to cover all the treatments being offered, be updated regularly, and go beyond published papers to overcome the reporting bias that affects much of the published research in the fertility field.
NICE together with HFEA should provide guidance on what is offered, and a recommendation for or against each intervention. The framework setting out which treatments should be offered in which populations should be clearer to reduce the potential for indication creep, whereby use is expanded from people who have clearly benefited to those for whom the evidence is much more shaky or non-existent. NICE should also consider adopting the GRADE system for making recommendations, which allows for strong (offer to everyone) or weak (offer to certain individuals) recommendations, with or without certain conditions. 18 Furthermore, recommendations should be based on live birth rates rather than pregnancy rates, which are inadequate for several reasons, not least because about 5% of pregnancies are lost between the first trimester and birth. 19 Guidance also needs continually updating if it is to be relevant and meaningful, particularly because of the growing number of For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe available tests, techniques, and treatments. Furthermore, clinics' awareness and uptake of guidance needs improving: a recent survey of 46 UK clinics licensed to provide intrauterine insemination found that although most clinics were aware of NICE guidance, only 10 clinics reduced the number of cycles or restricted its use according to NICE recommendations. 20 Currently, clinics vary widely in what they offer and there is a lack of clarity on what constitutes an add-on intervention. Clear classification systems and better information will aid understanding and ensure couples enter treatment fully informed.
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Key messages
Most treatments offered by UK fertility treatment centres are not supported by good evidence NICE provides clear advice on only 13 out 38 identified interventions, and systematic reviews were available for only 27
Information on harms is often poorly reported
Couples need clear advice on live birth rates and potential harms to make informed decisions Table   Table 1| Interventions with systematic reviews showing evidence of improved live birth rate Quality of evidence Effect on live birth rate: odds ratio (95% CI)
No of trials (participants) in review
High dropout rates and poor randomisation method descriptions for many trials meant the evidence was judged low quality. Differences in live birth rates were no longer significant (1.38 95% CI 0.96 to 1.99) after low quality studies were removed. Variable embryo transfer policies between groups 1.48 (1.20 to 1.82) compared with culture to day 2-3 13 (1630) Blastocyst culture 7 Evidence quality was moderate because of low participant numbers and limitations in the methods (in 5 studies both groups possibly received some unintentional endometrial injury). Removal of the low quality studies did not alter the effect estimate Relative risk 1.42 (1.08 to 1.85) compared with no injury 9 (1496) Endometrial scratching 8 In the three studies (n=324) that only assessed high versus no hyaluronic acid there was no significant effect (OR=1.35, 95% CI 0.86 to 2.12). Moreover, in some of the studies, multiple pregnancy rates were increased because more embryos were transferred per woman in the intervention groups 1.41 (1.17 to 1.69) compared with low or no hyaluronic acid 6 (1950) Adherence compounds 9 Only 44 live births recorded. One study had inadequate methods (the numbers of participants initially randomised to each group were not available) and a high unexplained dropout rate (26%); in another, the principal investigator had a commercial agreement with the manufacturer 4.21(2.08 to 8.51), 4 small trials (277) Oral antioxidants 10 For three other comparisons in the same review there was no significant effect on live birth rates 
